{"filing":{"accession_number":"0001213900-26-100350","cik":"0001860657","ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-16","report_date":"2026-09-15","primary_document":"ea0305570-8k_allarity.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026100350/ea0305570-8k_allarity.htm"},"events":[{"id":33776,"run_id":31077,"accession_number":"0001213900-26-100350","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces the Japan Patent Office's grant of Japanese Patent No. 7917283 covering Allarity's stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, with protection extending to 2039. This is a material intellectual property milestone for a clinical-stage pharmaceutical company, as it strengthens patent protection in Japan—described as \"one of the world's largest pharmaceutical markets\"—and supports the company's development and commercialization strategy for stenoparib. While this is an operational/strategic event (intellectual property protection), it does not fit the specific categories of earnings release, executive changes, M\u0026A, impairment, litigation, or other named event types, making operational_other the most appropriate classification.","company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","filing_date":"2026-09-16","form":"8-K","submitted_at":null,"items":[{"id":37303,"accession_number":"0001213900-26-100350","item_number":"8.01","item_title":"Other Matters.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the Japan Patent Office's grant of Japanese Patent No. 7917283 covering Allarity's stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, with protection extending to 2039. This is a material intellectual property milestone for a clinical-stage pharmaceutical company, as it strengthens patent protection in Japan—described as \"one of the world's largest pharmaceutical markets\"—and supports the company's development and commercialization strategy for stenoparib. While this is an operational/strategic event (intellectual property protection), it does not fit the specific categories of earnings release, executive changes, M\u0026A, impairment, litigation, or other named event types, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T12:02:39.855464+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37303,"accession_number":"0001213900-26-100350","item_number":"8.01","item_title":"Other Matters.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the Japan Patent Office's grant of Japanese Patent No. 7917283 covering Allarity's stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, with protection extending to 2039. This is a material intellectual property milestone for a clinical-stage pharmaceutical company, as it strengthens patent protection in Japan—described as \"one of the world's largest pharmaceutical markets\"—and supports the company's development and commercialization strategy for stenoparib. While this is an operational/strategic event (intellectual property protection), it does not fit the specific categories of earnings release, executive changes, M\u0026A, impairment, litigation, or other named event types, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T12:02:39.855464+00:00","company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","filing_date":"2026-09-16"}]}